Literature DB >> 17125866

Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer.

Michael Pinkawa1, Jaroslav Siluschek, Bernd Gagel, Cengiz Demirel, Branka Asadpour, Richard Holy, Michael J Eble.   

Abstract

BACKGROUND AND
PURPOSE: The aim of the study was to define the effect of different rectum fillings in the planning CT study on the posterior clinical target volume (CTV) displacements (PD) in primary and postoperative radiotherapy (RT) for prostate cancer.
MATERIALS AND METHODS: Fifty patients underwent CT scans in supine position with a full bladder and an empty bladder before RT and at several points in time during the treatment. PD were determined depending on the initial rectum volume (RV), average cross-sectional rectal area (CSA), and the rectal diameter at the level of the bladder neck (RD).
RESULTS: Posterior CTV motion was not found to be minimal with a particularly small initial rectum filling. Steeply increasing PD resulted for patients with RV>120cm(3), CSA>12cm(2), and RD>4.5cm. While below these critical values a posterior margin of 6mm/9mm allowed to cover 80%/90% of displacements, 18mm/24mm were needed for patients with larger rectum fillings. No correlation of increasing rectum distension with increasing PD was found at the apex level. PD could not be reduced by voiding the bladder.
CONCLUSIONS: Defining the posterior margin in prostate RT, the initial rectum distension and the superior-inferior CTV level has to be considered. Patients with large initial rectum fillings have preferentially the need for repeated planning CT scans or image-guided RT.

Entities:  

Mesh:

Year:  2006        PMID: 17125866     DOI: 10.1016/j.radonc.2006.10.028

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Which bowel preparation is best? Comparison of a high-fibre diet leaflet, daily microenema and no preparation in prostate cancer patients treated with radical radiotherapy to assess the effect on planned target volume shifts due to rectal distension.

Authors:  S Yahya; A Zarkar; E Southgate; P Nightingale; G Webster
Journal:  Br J Radiol       Date:  2013-08-30       Impact factor: 3.039

2.  Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion.

Authors:  Michael Pinkawa; Martin Pursch-Lee; Branka Asadpour; Bernd Gagel; Marc D Piroth; Jens Klotz; Sandra Nussen; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

3.  Analysis of inter-fraction setup errors and organ motion by daily kilovoltage cone beam computed tomography in intensity modulated radiotherapy of prostate cancer.

Authors:  Marcella Palombarini; Stefano Mengoli; Paola Fantazzini; Cecilia Cadioli; Claudio Degli Esposti; Giovanni Piero Frezza
Journal:  Radiat Oncol       Date:  2012-04-02       Impact factor: 3.481

Review 4.  Post-Prostatectomy Image-Guided Radiotherapy: The Invisible Target Concept.

Authors:  Florent Vilotte; Mickael Antoine; Maxime Bobin; Igor Latorzeff; Stéphane Supiot; Pierre Richaud; Laurence Thomas; Nicolas Leduc; Stephane Guérif; Jone Iriondo-Alberdi; Renaud de Crevoisier; Paul Sargos
Journal:  Front Oncol       Date:  2017-03-09       Impact factor: 6.244

5.  Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer.

Authors:  Shyama U Tetar; Anna M E Bruynzeel; Frank J Lagerwaard; Ben J Slotman; Omar Bohoudi; Miguel A Palacios
Journal:  Phys Imaging Radiat Oncol       Date:  2019-03-06

6.  Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.

Authors:  Gamze Ugurluer; Banu Atalar; Teuta Zoto Mustafayev; Gorkem Gungor; Gokhan Aydin; Meric Sengoz; Ufuk Abacioglu; Mustafa Bilal Tuna; Ali Riza Kural; Enis Ozyar
Journal:  Br J Radiol       Date:  2020-10-29       Impact factor: 3.039

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.